Sangamo Therapeutics, the zinc-finger gene-editing company, plans to expand its cell therapy pipeline by acquiring the French biotech firm TxCell for about $84 million. So far most cell therapies are intended to treat cancer, but TxCell is developing regulatory T-cell herapies for autoimmune diseases. Sangamo expects to begin a clinical trial next year using genetically engineered Tregs to prevent tissue rejection in organ-transplant patients.
Date: July 30, 2018
Source: c&en